冯炜红,杜学明

• 1:天津市北辰医院肿瘤科

摘要(Abstract)：

表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKIs)是伴有表皮生长因子受体(EGFR)基因突变的非小细胞肺癌(NSCLC)患者的一线治疗药物之一,其可有效延长患者总生存期,但部分患者存在耐药问题。新型EGFR TKIs、EGFR TKIs联合治疗、免疫治疗及个体化治疗有望解决NSCLC患者EGFR TKIs耐药问题。本文就NSCLC患者EGFR TKI耐药机制及其治疗方案的研究进展进行综述。

关键词(KeyWords)： 癌,非小细胞肺;蛋白酪氨酸激酶类;耐药;临床方案

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81372843)

作者(Author): 冯炜红,杜学明

参考文献(References)：

• [1]WHO.Cancer fact sheet no.297[R].2015.http://www.who.int/mediacentre/factsheets/fs297/en/(accessed March 9,2015).
• [2]PAEZ J G,JNNE P A,LEE J C,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,304(5676):1497-1500.
• [3]SHARMA S V,LEE D Y,LI B,et al.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J].Cell,2010,141(1):69-80.
• [4]BIVONA T G,HIERONYMUS H,PARKER J,et al.FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR[J].Nature,2011,471(7339):523-526.
• [5]LEE J K,SHIN J Y,KIM S,et al.Primary resistance to epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations:an exploratory study[J].Ann Oncol,2013,24(8):2080-2087.
• [6]ARASADA R R,AMANN J M,RAHMAN M A,et al.EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling[J].Cancer Res,2014,74(19):5572-5584.
• [7]FAN W,TANG Z,YIN L,et al.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents[J].Cancer Res,2011,71(13):4494-4505.
• [8]SEQUIST L V,YANG J C,YAMAMOTO N,et al.PhaseⅢstudy of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J].J Clin Oncol,2013,31(27):3327-3334.
• [9]YASUDA H,KOBAYASHI S,COSTA D B.EGFR exon 20 insertion mutations in non-small-cell lung cancer:preclinical data and clinical implications[J].Lancet Oncol,2012,13(1):e23-31.
• [10]YASUDA H,PARK E,YUN C H,et al.Structural,biochemical,and clinical characterization of epidermal growth factor receptor(EGFR)exon 20 insertion mutations in lung cancer[J].Sci Transl Med,2013,5(216):216ra177.
• [11]GANDARA D R,LI T,LARA P N,et al.Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer:approach to subtyping progressive disease and clinical implications[J].Clin Lung Cancer,2014,15(1):1-6.
• [12]WEICKHARDT A J,SCHEIER B,BURKE J M,et al.Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer[J].J Thorac Oncol,2012,7(12):1807-1814.
• [13]YU H A,ARCILA M E,REKHTMAN N,et al.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in155 patients with EGFR-mutant lung cancers[J].Clin Cancer Res,2013,19(8):2240-2247.
• [14]KOBAYASHI S,BOGGON T J,DAYARAM T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
• [15]YUN C H,MENGWASSER K E,TOMS A V,et al.The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[J].Proc Natl Acad Sci USA,2008,105(6):2070-2075.
• [16]BALAK M N,GONG Y,RIELY G J,et al.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors[J].Clin Cancer Res,2006,12(21):6494-6501.
• [17]BEAN J,RIELY G J,BALAK M,et al.Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma[J].Clin Cancer Res,2008,14(22):7519-7525.
• [18]COSTA D B,HALMOS B,KUMAR A,et al.BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations[J].PLo S Med,2007,4(10):1669-1679;discussion 1680.
• [19]SEQUIST L V,WALTMAN B A,DIAS-SANTAGATA D,et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J].Sci Transl Med,2011,3(75):75ra26.
• [20]TAKEZAWA K,PIRAZZOLI V,ARCILA M E,et al.HER2amplification:a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation[J].Cancer Discov,2012,2(10):922-933.
• [21]OHASHI K,SEQUIST L V,ARCILA M E,et al.PNAS Plus:Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS,NRAS,or MEK1[J].Proc Natl Acad Sci USA,2012,109:E2127-2133.
• [22]ZHANG Z,LEE J C,LIN L,et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J].Nat Genet,2012,44(8):852-860.
• [23]ALAM N,GUSTAFSON K S,LADANYI M,et al.Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung[J].Clin Lung Cancer,2010,11(5):E1-4.
• [24]SUDA K,TOMIZAWA K,FUJII M,et al.Epithelial to mesenchymal transition in an epidermal growth factor receptormutant lung cancer cell line with acquired resistance to erlotinib[J].J Thorac Oncol,2011,6(7):1152-1161.
• [25]NCCN.NCCN guidelines[R].http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf(accessed Jan 5,2015).
• [26]GOLDBERG S B,OXNARD G R,DIGUMARTHY S,et al.Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors[J].Oncologist,2013,18(11):1214
• [27]CHMIELECKI J,FOO J,OXNARD G R,et al.Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling[J].Sci Transl Med,2011,3(90):90ra59.
• [28]CHAFT J E,OXNARD G R,SIMA C S,et al.Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFRmutant lung cancer and acquired resistance to erlotinib or gefitinib:implications for clinical trial design[J].Clin Cancer Res,2011,17(19):6298-6303.
• [29]SORIA J C,WU Y L,NAKAGAWA K,et al.Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on firstline gefitinib(IMPRESS):a phase 3 randomised trial[J].Lancet Oncol,2015,16(8):990-998.
• [30]OU S H.Second-generation irreversible epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs):a better mousetrap?A review of the clinical evidence[J].Crit Rev Oncol Hematol,2012,83(3):407-421.
• [31]MILLER V A,HIRSH V,CADRANEL J,et al.Afatinib versus placebo for patients with advanced,metastatic non-small-cell lung cancer after failure of erlotinib,gefitinib,or both,and one or two lines of chemotherapy(LUX-Lung 1):a phase 2b/3 randomised trial[J].Lancet Oncol,2012,13(5):528-538.
• [32]REGALES L,GONG Y,SHEN R,et al.Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer[J].J Clin Invest,2009,119(10):3000-3910.
• [33]AKBAY E A,KOYAMA S,CARRETERO J,et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J].Cancer Discov,2013,3(12):1355-1363.
• [34]MURTAZA M,DAWSON S J,TSUI D W,et al.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA[J].Nature,2013,497(7447):108-112.
• [35]PUNNOOSE E A,ATWAL S,LIU W,et al.Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib[J].Clin Cancer Res,2012,18(8):2391-2401.
• [36]MAHESWARAN S,SEQUIST L V,NAGRATH S,et al.Detection of mutations in EGFR in circulating lung-cancer cells[J].N Engl J Med,2008,359(4):366-377.

文章评论(Comment)：